AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JUN 3 - (NewsRx.com & NewsRx.net) -- Nastech Pharmaceutical Co., Inc., (NSTK) has commenced a phase I clinical trial to evaluate intranasal administration of human parathyroid hormone 1-34 (PTH1-34) in healthy subjects.
"We are pleased to have added PTH1-34 to a list of nasal dosage forms of large-molecule peptides and proteins that Nastech has tested in humans," stated Steven C. Quay, MD, PhD, chairman, president, and chief executive officer. "PTH1-34 Nasal Spray, for which we have filed patent applications, represents an important opportunity to expand our portfolio of intranasal dosage forms based on our proprietary Tight Junction drug-delivery technology. The potential global market for a nasal spray dosage form of PTH1-34 is significant."
PTH1-34 is a fragment of the naturally occurring human parathyroid hormone that is an important regulator of calcium and phosphorus metabolism. When given by daily injection, PTH1-34 has been shown to increase bone mineral density (BMD) and significantly ...
Source: HighBeam Research, Company initiates intranasal parathyroid hormone clinical development.